Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Cook

Showing results (461-470 of 470) with videos related to

Pageof 47
Sort By:
You have reached the last page of results.This site can display upto 470 results.
Acta Neuropathologica Communications|April 29, 2023
Patients with sporadic FTLD exhibit similar increases in lysosomal proteins and storage material as patients with FTD due to GRN mutationsSkylar E Davis, Anna K Cook, Justin A Hall, et al.
Neurobiology of Disease|June 9, 2026
Human TDP-43 expression worsens FTD-related phenotypes in progranulin-insufficient miceAnna K Cook, Benjamin Lin, Yumo Song, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.
Journal of Medicinal Chemistry|January 2, 2010
Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition modelsChristopher J O'Donnell, Bruce N Rogers, Brian S Bronk, et al.
JAMA Network Open|October 5, 2023
Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical TrialsPaul A Harris, Sarah E Dunsmore, Jane C Atkinson, et al.
Journal of Medicinal Chemistry|July 11, 2006
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationshipDonn G Wishka, Daniel P Walker, Karen M Yates, et al.
Scientific Reports|October 16, 2023
Simultaneous bright- and dark-field X-ray microscopy at X-ray free electron lasersLeora E Dresselhaus-Marais, Bernard Kozioziemski, Theodor S Holstad, et al.
Contemporary Clinical Trials|May 5, 2026
Conducting multicenter trials through the trial innovation network comprehensive consultationDaniel F Hanley, Karen Lane, Nichol McBee, et al.
Journal of Clinical and Translational Science|July 30, 2025
Insights from the trial innovation network's initial consultation processPaul A Harris, Nan Kennedy, Consuelo H Wilkins, et al.
JAMA Network Open|May 29, 2025
Enhancing Multicenter Trials With the Trial Innovation Network's Initial Consultation ProcessPaul A Harris, Consuelo H Wilkins, Karen Lane, et al.
Pageof 47

Showing results (461-470 of 470) with videos related to

Sort By:
Pageof 47
You have reached the last page of results.This site can display upto 470 results.
Acta Neuropathologica Communications|April 29, 2023
Patients with sporadic FTLD exhibit similar increases in lysosomal proteins and storage material as patients with FTD due to GRN mutationsSkylar E Davis, Anna K Cook, Justin A Hall, et al.
Neurobiology of Disease|June 9, 2026
Human TDP-43 expression worsens FTD-related phenotypes in progranulin-insufficient miceAnna K Cook, Benjamin Lin, Yumo Song, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1997
CHOP-based chemotherapy is as effective as alternating PEEC/CHOP chemotherapy in a randomised trial in high-grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma GroupD A Cameron, J M White, S J Proctor, et al.
Journal of Medicinal Chemistry|January 2, 2010
Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition modelsChristopher J O'Donnell, Bruce N Rogers, Brian S Bronk, et al.
JAMA Network Open|October 5, 2023
Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical TrialsPaul A Harris, Sarah E Dunsmore, Jane C Atkinson, et al.
Journal of Medicinal Chemistry|July 11, 2006
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationshipDonn G Wishka, Daniel P Walker, Karen M Yates, et al.
Scientific Reports|October 16, 2023
Simultaneous bright- and dark-field X-ray microscopy at X-ray free electron lasersLeora E Dresselhaus-Marais, Bernard Kozioziemski, Theodor S Holstad, et al.
Contemporary Clinical Trials|May 5, 2026
Conducting multicenter trials through the trial innovation network comprehensive consultationDaniel F Hanley, Karen Lane, Nichol McBee, et al.
Journal of Clinical and Translational Science|July 30, 2025
Insights from the trial innovation network's initial consultation processPaul A Harris, Nan Kennedy, Consuelo H Wilkins, et al.
JAMA Network Open|May 29, 2025
Enhancing Multicenter Trials With the Trial Innovation Network's Initial Consultation ProcessPaul A Harris, Consuelo H Wilkins, Karen Lane, et al.
Pageof 47